Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2016

View Archived Issues

EDP-305 is a novel potent FXR agonist with promising efficacy in vitro and in vivo

AstraZeneca patents FLAP and leukotriene synthesis inhibitors

Mutabilis discloses beta-lactamase inhibitors

Entyvio receives positive reimbursement recommendation in Canada

Hepatitis C candidate EDP-494 shows promise in early clinical trial

Novel dexamethasone prodrug ZSJ-0228 has lower systemic exposure, improved safety

Shionogi signs license agreement with Tokushima University for novel type A2 Botulinum toxin

Canadian Stem Cell Network announces funding to support stem cell research

First patient given allogeneic adipose tissue-derived multilineage progenitor cells in phase I study

Kymab raises Series C financing to advance antibody pipeline

NVIDIA Foundation awards grant to TGen to support technology efforts in cancer

Novel BTK mutation may cause ibrutinib resistance

Anavex offers 41-week update from phase IIa study of ANAVEX 2-73 in mild to moderate Alzheimer's

Lysyl oxidase homolog 2 identified as a therapeutic target for liver fibrosis

Verseon describes novel direct thrombin inhibitor VE-1902

Janssen-Cilag seeks approval of guselkumab in Europe

FN1 is significantly upregulated in ASM vs. ISM

AiCuris conducting new preclinical study of AIC-649 with support from NIAID

GlaxoSmithKline begins phase III program for daprodustat in anemia associated with CKD

Researchers test new highly potent FXR agonist, EP-024297

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...